Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?
Yıl: 2020 Cilt: 62 Sayı: 3 Sayfa Aralığı: 151 - 156 Metin Dili: İngilizce DOI: 10.4274/gulhane.galenos.2020.793 İndeks Tarihi: 21-10-2020
Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?
Öz: Aims: Early diagnosis and treatment can improve the prognosis of patients with gastric cancer. Therefore, identification and follow-up of patients who are under the risk of gastric cancer can improve the success of treatment and quality of life.Methods: In our study, cyclooxygenase-2 (COX2) and P21 expressions of the patients with gastric adenocarcinoma and its precursor lesions atrophic gastritis and intestinal metaplasia were examined retrospectively with the immunohistochemical method.Results: Forty patients were enrolled in each group. Grade and intensity of COX2 expressions were high in all three groups in accordance with the literature. In contrast with COX2 expressions, the grade and intensity of P21 expressions were very low in all three groups. Expressions of P21 were not observed in the vast majority of the gastric cancer group. Due to slight expressions, we detected statistically significant differences in both grading and intensity of P21 expressions between precancerous lesions and gastric cancer.Conclusions: High COX2 expressions were consistent with literature. Decreased P21 expressions can reveal the relationship between loss of P21 expression and poor prognosis. Increased COX2, expression, especially in atrophic gastritis patients, and decreased P21 expression may be used in the follow-up of patients with gastric cancer and its precursor lesions.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- Eberhart CE, Dubois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology. 1995;109:285-301.
- Lim HY, Joo HJ, Choi JH, et al. Increased expression of cycloxygenase-2 protein in human gastric carcinoma. Clin Cancer Res. 2000;6:519-525.
- Mizuno H, Sakomoto C, Matsuda K, et al. Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing mice. Gastroenterology. 1997;112:387-397.
- Van Rees BP, Saukkonen K, Ristimaki A, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol. 2002;196:171-179.
- Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G. yclooxygenase 2 expression in Barrett’s esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology. 2000;118:487- 496.
- Türkmen IÇ, Başsüllü N, Uraz S, Yerdel MA, Memışoğlu R, Bülbül Doğusoy G. CDX2, COX2 and MUC2 expressions in Barrett’s esophagus; Can they be useful in determination of the dysplasia. Turk Patoloji Derg. 2012;28:251-258.
- Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The P21, interacting protein Cip 1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75:805-816.
- Czerniak B, Herz F, Koss LG, Schlom J. Ras oncogene as P21 as a tumor marker in cytodiagnosis of gastric and colonic carcinomas. Cancer. 1987;60:2432-2436.
- Ristimaki A, Sivula A, Ludin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632-635.
- Kimura A, Tsuji S, Tsujii M, et al. Expression of COX2 and nitrotyrosine in human gastric mucosa before and after Helicobacter Pylori eradication. Prostaglandins Leukot Essent Fatty Acids. 2000;63:315-322.
- Saukkonen K, Nieminen O, Van Rees B, et al. Expression of COX2 in the dysplasia of the stomach and in intestinal type gastric adenocarcinoma. Clin Cancer Res. 2001;7:1923-1931.
- Rossolymos NA, Papatheodoridis G, Tsakoniatis M, Dimitrios K, Lazaris A. Expression of cyclooxygenase-2 in gastritis and gastric premalignant lesions. Ann Gastroenterol. 2013;26:275.
- Wang J, Chi DS, Kalin GB, et al. Helicobacter Pylori infection and oncogene expressions in gastric cancer and its precursor lesions. Dig Dis Sci. 2002;47:107-113.
- Sun Y, Li JY, He JS, Zhou LX, Chen K. Tissue microarray analysis of multiple gene expression in intestinal metaplasia, dysplasia, and carcinoma of the stomach. Histopathology. 2005;46:505-514.
- Noguchi M, Hirohashi S, Shimosato Y, et al. Histologic demonstration of antigens reactive with anti-P21 Ras monoclonal antibody (RAP-5) in human stomach Cancers. J Natl Cancer Inst. 1986;77:379-385.
- Craanen ME, Blok P, Offerhaus GJ, et al. P21(Waf/Cip1) expression and P53/MDM2 feedback loop in gastric carcinogenesis. J Pathol. 1999;189:481-486.
- Nomura A, Stemmermann GN, Chyou PH, Kato I, PerezPerez GI, Blaser MJ. Helicobacter Pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325:1132-1136.
- Ogawa M, Maeda K, Onoda N, Chung YS, Sowa M. Loss of p21WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. Br J Cancer. 1997;5:1617-1620.
- Liu X, Yu H, Cai H, Wang Y. Expression of CD24, p21, p53, and c-myc in alpha-fetoprotein producing gastric cancer: correlation with clinicopathologic characteristics and survival. J Surg Oncol. 2014;109:859-864.
- Gunia S, Kakies C, Erbersdobler A, Hakenberg OW, Koch S, May M. Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis. J Clin Pathol. 2012;65:232-236.
- Gamboa-Dominguez A, Seidl S, Reyes-Gutierrez E, et al. Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and Ecadherin expression in gastric cancer. J Clin Pathol. 2007;60:756-761.
- Kouraklis G, Katsoulis IE, Theocharis S, et al. Does the expression of cyclin E, pRb, and p21 correlate with prognosis in gastric adenocarcinoma? Dig Dis Sci. 2009;54:1015-1020.
- Ozen A, Kocak Z, Sipahi T, et al. The prognostic significance of p21 and Her2 gene expression and mutation/polymorphism in patients with gastric adenocarcinoma. Med Oncol. 2013;30:357-362.
- Karadurmuş N, Ertürk İ. Which is the best for cancer treatment? Surgery or chemotherapy. J Oncol Sci. 2017;3:32-33.
| APA | yesillik s, alömeroğlu m, yildiz b, BAŞGÖZ B, Gülşen M (2020). Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?. , 151 - 156. 10.4274/gulhane.galenos.2020.793 |
| Chicago | yesillik sait,alömeroğlu melih,yildiz birol,BAŞGÖZ Bilgin Bahadır,Gülşen Mustafa Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?. (2020): 151 - 156. 10.4274/gulhane.galenos.2020.793 |
| MLA | yesillik sait,alömeroğlu melih,yildiz birol,BAŞGÖZ Bilgin Bahadır,Gülşen Mustafa Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?. , 2020, ss.151 - 156. 10.4274/gulhane.galenos.2020.793 |
| AMA | yesillik s,alömeroğlu m,yildiz b,BAŞGÖZ B,Gülşen M Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?. . 2020; 151 - 156. 10.4274/gulhane.galenos.2020.793 |
| Vancouver | yesillik s,alömeroğlu m,yildiz b,BAŞGÖZ B,Gülşen M Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?. . 2020; 151 - 156. 10.4274/gulhane.galenos.2020.793 |
| IEEE | yesillik s,alömeroğlu m,yildiz b,BAŞGÖZ B,Gülşen M "Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?." , ss.151 - 156, 2020. 10.4274/gulhane.galenos.2020.793 |
| ISNAD | yesillik, sait vd. "Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?". (2020), 151-156. https://doi.org/10.4274/gulhane.galenos.2020.793 |
| APA | yesillik s, alömeroğlu m, yildiz b, BAŞGÖZ B, Gülşen M (2020). Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?. Gülhane Tıp Dergisi, 62(3), 151 - 156. 10.4274/gulhane.galenos.2020.793 |
| Chicago | yesillik sait,alömeroğlu melih,yildiz birol,BAŞGÖZ Bilgin Bahadır,Gülşen Mustafa Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?. Gülhane Tıp Dergisi 62, no.3 (2020): 151 - 156. 10.4274/gulhane.galenos.2020.793 |
| MLA | yesillik sait,alömeroğlu melih,yildiz birol,BAŞGÖZ Bilgin Bahadır,Gülşen Mustafa Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?. Gülhane Tıp Dergisi, vol.62, no.3, 2020, ss.151 - 156. 10.4274/gulhane.galenos.2020.793 |
| AMA | yesillik s,alömeroğlu m,yildiz b,BAŞGÖZ B,Gülşen M Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?. Gülhane Tıp Dergisi. 2020; 62(3): 151 - 156. 10.4274/gulhane.galenos.2020.793 |
| Vancouver | yesillik s,alömeroğlu m,yildiz b,BAŞGÖZ B,Gülşen M Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?. Gülhane Tıp Dergisi. 2020; 62(3): 151 - 156. 10.4274/gulhane.galenos.2020.793 |
| IEEE | yesillik s,alömeroğlu m,yildiz b,BAŞGÖZ B,Gülşen M "Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?." Gülhane Tıp Dergisi, 62, ss.151 - 156, 2020. 10.4274/gulhane.galenos.2020.793 |
| ISNAD | yesillik, sait vd. "Can Increased or Decreased COX2 and P21 Expression be Used in Illness Monitoring of Gastric Cancer and Its Potential Precursor Lesions?". Gülhane Tıp Dergisi 62/3 (2020), 151-156. https://doi.org/10.4274/gulhane.galenos.2020.793 |
